Feed / CGON

CG Oncology, Inc.

CGON

Healthcare · 79.78 +2.8% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

CG Oncology, Inc.'s move is being confirmed by its market group.

CGON accounts for 11.2% of the group's measured movement across 6.0 effective names. raw member direction is mixed; 6 of 8 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveCounter-move#5 of 8 by movement share
Group movement share11.2%Absolute path energy—not portfolio weight
Relative path+1.34%counter
Effective breadth6.0 / 8broad
Relative alignment6/8downside path · 1 counter-moving
Capital-flow agreement15%not yet clean
SEQUENCE READ

IBRX, BBIO, ARWR moved materially before CGON. CGON crossed its material path threshold at 11:50 ET, 45 minutes after the first measured mover. BEAM followed.

EVIDENCE COVERAGE

5 of 8 members in Gene Editing Therapies are active. 0 of 4 disclosed connections are confirming.

What would change this read
  • At least 6 of 8 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as RLYB begins moving with the group.

Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.

Watch this read

Who this business touches

The relationships behind CGON

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

JEFJefferies Financial Group Inc.investeeMay 8, 2026

On March 28, 2025, we entered into an Open Market Sale Agreement SM (Jefferies Sales Agreement) with Jefferies LLC, as agent, pursuant to which we may offer and sell, from time to time through Jefferies, shares of our common stock.

MRKMerck & Company, Inc.partnerFeb 27, 2026

We entered into a clinical trial collaboration and supply agreement with Merck providing at no-cost supply of pembrolizumab for use in CORE-001 (which agreement also provides for the joint ownership of clinical trial data but has no additional financial oblig…

Depended on by

URGNUroGen Pharma Ltd.competitorMar 2, 2026

We are aware of several pharmaceutical companies that are developing drugs in the general fields of urology and uro-oncology, such as AstraZeneca, Aura Biosciences., Bristol Myers Squibb, CG Oncology, enGene Holdings, Ferring Pharmaceuticals, Fidia Pharmaceut…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CGON is currently a Early Follower in the organic co-movement group Gene Editing Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.